BioCentury
ARTICLE | Politics & Policy

Study warns against flooding Priority Review voucher market

May 5, 2016 1:45 AM UTC

An analysis published in Health Affairs cautioned against expanding Priority Review voucher programs to prevent excess supply from reducing the vouchers' value and lowering companies' incentives to develop new drugs for eligible diseases.

The researchers estimated the value of a hypothetical Priority Review voucher would fall from $234 million if it were the only one on the market to $39-$79 million if four vouchers were available. ...